Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of JSKN003 combination therapy in HER2-positive first-line advanced/metastatic gastric cancer and perioperative resectable gastric cancer
CTR20251968Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab repodatecan in gastric cancer (GC), HER2-overexpressing gastric carcinoma, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Jun 2025; status: active.
02
Drugs
anbenitamab repodatecan
03
Conditions
gastric cancer (GC)HER2-overexpressing gastric carcinoma
Beyond the preview
Go deeper on CTR20251968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251968.